M33.21

Clinical Causes: Autoimmune response where the immune system mistakenly attacks muscle tissue Genetic predispositions may increase vulnerability Environmental factors, such as infections or exposure to certain chemicals, potentially trigger the disease Other connective tissue diseases or inflammatory conditions might be associated

Key Symptoms: Progressive muscle weakness, especially in the hips, shoulders, neck, and back Difficulty swallowing or speaking in severe cases Respiratory symptoms such as shortness of breath, especially during physical activity or when lying down Fatigue and general malaise Muscle pain or tenderness In cases with lung involvement, symptoms like persistent cough and chest discomfort may occur

Diagnosis Path: Physical examination to assess muscle strength and joint health Blood tests that detect elevated levels of muscle enzymes like creatine kinase (CK), indicating muscle damage Electromyography (EMG) to measure electrical activity in muscles Muscle biopsy to identify inflammation and muscle fiber damage Imaging studies, such as MRI, to visualize muscle inflammation Pulmonary function tests to evaluate respiratory capacity and identify lung impairment Chest X-rays or CT scans to assess lung involvement

Treatment Protocols: Immunosuppressive medications, including corticosteroids, are often the first line of treatment to reduce inflammation Additional immunosuppressants like azathioprine or methotrexate may be prescribed for long-term management Physical therapy to maintain muscle strength and flexibility Speech and swallowing therapy if these functions are affected Mohre recent treatments focus on respiratory support, including the use of oxygen therapy or ventilatory support in severe cases Regular monitoring of lung function and muscle strength to assess disease progression and treatment response